Prerana Sahu, Anjali, Gyanesh Kumar Sahu, Harish Sharma, Chanchal Deep Kaur
Prerana Sahu1, Anjali1, Gyanesh Kumar Sahu1, Harish Sharma1, Chanchal Deep Kaur2
1Shri Shankaracharya Group of Institution, Faculty of Pharmacy, Junwani, Bhilai (C.G.).
2Shri Rawatpura Sarkar Institute of Pharmacy, Kumhari (C.G.).
Volume - 13,
Issue - 4,
Year - 2020
Cardiac arrest is the abrupt loss of heart function in a person who may or may not have been diagnosed with heart disease. Cardiac arrest may be caused by irregular heart rhythms, called arrhythmias. A common arrhythmia associated with cardiac arrest is ventricular fibrillation. Ventricular fibrillation means that the heart’s lower chambers suddenly start beating chaotically and don’t pump blood. Cardiac arrest is the sudden cessation of cardiac mechanical activity because of dysrhythmia or electromechanical dissociation. Unless reversed within minutes, cardiac arrest results in lethal brain and other end-organ damage. Epinephrine is the primary drug administered during cardiopulmonary resuscitation (CPR) to reverse cardiac arrest. Epinephrine increases arterial blood pressure and coronary perfusion during CPR via alpha-1-adrenoceptor agonist effects. The main objective of this study was to prepare the optimized formulation of Trandermal patches of epinephrine for the treatment of cardiac arrest. Transdermal drug delivery (TDD) is a non-invasive route of drug administration, although its applications are limited by low skin permeability. It is an attractive alternative technique over the conventional techniques for administration of systemic approaches. For both local and systemic effects skin is the major site of application. However, to penetrate the drug through skin, stratum corneum is the main barrier. This study is further aimed to analyse, concentration of drug reaching in the body and to study its effect.
Cite this article:
Prerana Sahu, Anjali, Gyanesh Kumar Sahu, Harish Sharma, Chanchal Deep Kaur. Formulation, Characterization and Ex vivo Evaluation of Epinephrine Transdermal Patches. Research J. Pharm. and Tech. 2020; 13(4):1684-1692. doi: 10.5958/0974-360X.2020.00305.4
1. Losquadro WD. Anatomy of the Skin and the Pathogenesis of Nonmelanoma Skin Cancer. Facial Plastic Surgery Clinics. 2017 Aug 1;25(3):283-9.
2. Som PM, Laitman JT, Mak K. Embryology and Anatomy of the Skin, Its Appendages, and Physiologic Changes in the Head and Neck. Neurographics. 2017 Oct 1;7(5):390-415.
3. Somagoni J, Boakye CH, Godugu C, Patel AR, Faria HA, Zucolotto V, Singh M. Nanomiemgel-A novel drug delivery system for topical application-in vitro and in vivo evaluation. PLoS One. 2014 Dec 29;9(12): e115952.
4. Stojic M, Lopez V, Montero A, Quílez C, de Aranda Izuzquiza G, Vojtova L, Jorcano JL, Velasco D. Skin tissue engineering 3. Biomaterials for Skin Repair and Regeneration. 2019 Jun 18:59.
5. Bouwstra JA, Ackaert O, Eikelenboom J, Wolff HM, inventors; UCB Pharma GmbH, assignee. Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis. United States Patent US 8,754,120. 2014 Jun 17.
6. El Maghraby GM. Occlusive Versus Nonocclusive Application in Transdermal Drug Delivery. In Percutaneous Penetration Enhancers Drug Penetration Into/Through the Skin 2017 (pp. 27-33). Springer, Berlin, Heidelberg.
7. Zheng Y, Ouyang WQ, Wei YP, Syed SF, Hao CS, Wang BZ, Shang YH. effects of carbopol® 934 proportion on nanoemulsion gel for topical and transdermal drug delivery: a skin permeation study. International Journal of Nanomedicine. 2016; 11:5971
8. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. European Journal of Pharmaceutical Sciences. 2001 Sep 1;14(2):101-14.
9. Valenta C, Auner BG. The use of polymers for dermal and transdermal delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2004 Sep 1;58(2):279-89.
10. Tracton AA. Coatings Materials and Surface Coatings. CRC Press; 2006 Nov 7.
11. Sanghai P, Nandgude T, Poddar S. Formulation of bilayer benzydamine HCl patch targeted for gingivitis. Journal of Drug Delivery. 2016;2016.
12. Gupta R, Mukherjee B. Development and in vitro evaluation of diltiazem hydrochloride transdermal patches based on povidone–ethylcellulose matrices. Drug Development and Industrial Pharmacy. 2003 Jan 1;29(1):1-7.
13. Kandavilli S, Nair V, Panchagnula R. Polymers in transdermal drug delivery systems. Pharmaceutical Technology. 2002 May;26(5):62-81.
14. Sachan R, Bajpai M. Transdermal Drug Delivery System: A Review. Int J Res Dev Pharm Life Sci 2013; 3: 748-765
15. Dedakia A, Matholiya C, Koyani V, Bhimani D. Three generations: pimary, secondary and tertiary generations of transdermal drug delivery systems: A review. Int J Pharm Sci Res. 2013 Jun 1;4(6):2159-73.
16. Shingade GM, Aamer Q, Sabale PM, Grampurohit ND, Gadhave MV. Review on: recent trend on transdermal drug delivery system. J Drug Deliv Ther 2012; 1: 66-75
17. Wallace SM, Ridgeway B, Jun E. Topical delivery of Lodocaine in healthy volunteers by Electroporation, Electroincorporation, or Iontoporesis: An evaluation of skin Anesthesia. Reg Anesth Pain Med 2001; 26: 229-238.
18. Patel D, Chaudhary SA. Transdermal Drug Delivery System: A Review. Pharma Innovat 2012; 1: 66-75.
19. Rawat S, Vengurlekar S, Rakesh B, Jain S, Srikarti G. Transdermal delivery by iontophoresis. Indian J Pharm Sci 2008; 70: 5-10
20. Menegazzi JJ, Callaway CW, Sherman LD, et al. Ventricular fibrillation scaling exponent can guide timing of defibrillation and other therapies. Circulation 2004; 109:926–931
21. Attama A, Akpa PA, Onugwu LE, Igwilo G. Novel buccoadhesive delivery system of hydrochlorothiazide formulated with ethylcellulose hydroxypropyl methylcellulose interpolymer complex. Scientiﬁc Res Essay. 2008;3(6):26–33
22. Nafee NA, Ahemed F, Borale A. Preparation and evaluation of mucoadhesive patches for delivery of cetylpyridinium chloride (CPC). Acta Pharma. 2003; 199–212
23. Verma N, Wahi AK, Verma A, Chattopadhayay P. Evaluation ofa mucoadhesive buccal patch for delivery of atenolol: in vitroscreening of bioadhesion. J Pure Appl Microbiol. 2007; 1:115–8
24. Attama A, Akpa PA, Onugwu LE, Igwilo G. Novel buccoadhesive delivery system of hydrochlorothiazide formulated with ethyl cellulose hydroxypropyl methylcellulose interpolymer complex. Scientific Res Essay. 2008; 3(6):26–33.
25. Pandit V, Khanum A, Bhaskaran S, Banu V. Formulation and evaluation of transdermal films for the treatment of overactive bladder. Int J Pharm Tech Res. 2009;1: 799–804.
26. Shaila L, Pandey S, Udupa N. Design and evaluation of matrix type membrane controlled Transdermal drug delivery system of nicotin suitable for use in smoking cessation. Indian. Jour. Pharm. Sci. 2006; 68: 179-84.
27. Aggarwal G, Dhawan S. Development, fabrication and evaluation of transdermal drug delivery system - A review. Pharmainfo.net. 2009.
28. Vyas SP, Khar RK. Controlled drug delivery concepts and advances. Vallabh Prakashan. 2002; 1:411-47.
29. Verma PRP, Iyer SS. Transdermal delivery of propranolol using mixed grades of Eudragit: Design and in vitro and in vivo evaluation. Drug. Dev. Ind. Pharm. 2000; 26: 471-6.
30. Gannu R, Vamshi VY, Kishan V, Rao MY. Development of nitrendipine transdermal patches: In vitro and ex vivo characterization. Current. Drug. Delivery. 2007; 4: 69-76.
31. Gordon RA, Peterson TA. Four myths about transdermal drug delivery. Drug Delivery Technology. 2003; 3: 1-7.
32. Williams AC, Barry BW. Penetration enhancers, Advanced drug Delivery Reviews. 2004; 56: 603-18
33. Karande P, Jain A, Ergun K, Kispersky V, Mitragotri S. Design principles of chemical penetration enhancers for transdermal drug delivery, Proceedings of the national academy of sciences of the United States of America. 2005; 102: 4688-93.
34. Foco A, Hadziabdic J, Becic F. Transdermal drug delivery systems. Med. Arch 2004; 58: 230-4.
35. Khengar R.H., Jones S.A., Turner R.B., Forbes B., Brown M.B. Nail swelling as a pre-formulation screen for the selection and optimisation of ungual penetration enhancers. Pharm. Res. 2007; 24:2207–2212.
36. Simon A., Amaro M.I., Healy A.M., Cabral L.M., de Sousa V.P. Comparative evaluation of rivastigmine permeation from a transdermal system in the Franz cell using synthetic membranes and pig ear skin with in vivo-in vitro correlation. Int. J. Pharm. 2016; 512:234–241.
37. Kulkarni K.N., Datta-Gupta A. Estimating Relative Permeability from Production Data: A Streamline Approach. SPE J. 2000; 5:402–411.
38. Sahu GK, Sharma H, Gupta A, Kaur CD. Advancements in microemulsion based drug delivery systems for better therapeutic effects. Int J Pharm Sci Dev Res 1 (1): 008. 2015;15(008).
39. Wahane AR, Karankal S, Sharma P, Khutel D, Singh O, Shardul V, Sabha N, Dewangan J, Dewangan A, Jangde A, Rani C. Pharmaceutical Aspects on the Formulations of Hydrogel: An Update. Research Journal of Pharmaceutical Dosage Forms and Technology. 2018 Jun 20;10(2):79-84.
40. Dapurkar KV, Sahu KG, Sharma H, Meshram S, Rai G. Anti-arthritic activity of roots extract of Boerhaavia diffusa in adjuvant induced arthritis rats. Sch Acad J Pharm. 2013;2(2):107-9.
41. Gupta SS, Sahu G, Sharma M, Chandrakar S, Sahu VD, Sharma G, Dewangan K, Solanki H, Majumdar M, Tripathi DK, Alexander A. Preparation and Optimization of floating microbeads of ciprofloxacin HCl. Research Journal of Pharmacy and Technology. 2016 Jul 1; 9(7):848.
42. Tripathi S, Kumar Sahu U, Tripathi DK, Alexander A, Sharma H, Sahu GK. Formulation and characterization of Virgin Coconut Oil Emulsion (VCOE) for treatment of Alzheimer’s disease. Research Journal of Pharmaceutical Dosage Forms and Technology. 2018 Jun 20;10(2):49-54.
43. Agrawal OP, Agrawal S. An overview of new drug delivery system: microemulsion. Asian J Pharm Sci Tech. 2012; 2(5-12).
44. Sahu GK, Sharma H, Kaur CD. Evolving Concepts and Targeting of Arthritis.
45. Sahu G, Sharma H, Kaur CD. A Novel Approach of Magnetic Modulated Microspheres. science. 2013; 2:5.
46. Sahu G, Sharma H, Dapurkar V, Rai G. Research article; Development and Evaluation of Methotraxate Loaded BSA Microspheres; Int. Res J Pharm. App Sci.; 2012, 2(5): 9-12
47. Bhandarkar A, Sahu SK, Yadav P, Sahu K, Dewangan D, Thapa H, Verma VS, Sharma M, Tripathi DK, Alexander A, Bhatt A. Formulation and Evaluation of Ascorbic acid Lozenges for the treatment of Oral Ulcer. Research Journal of Pharmacy and Technology. 2018 Apr 1;11(4):1307-12.
48. Sharma H, Dapurkar VK, Rai G, Sahu GK. Microemulsions for the Topical Administration of 5-Fluorouracil: Preparation and Evaluation. Research Journal of Pharmacy and Technology. 2012 Aug 1;5(8):5.
49. Tripathi S, Kumar Sahu U, Tripathi DK, Alexander A, Sharma H, Sahu GK. Formulation and characterization of Virgin Coconut Oil Emulsion (VCOE) for treatment of Alzheimer’s disease. Research Journal of Pharmaceutical Dosage Forms and Technology. 2018 Jun 20;10(2):49-54.
50. Jadhav RT, Kasture PV, Gattani SG, Surana SJ. Formulation and evaluation of transdermal films of diclofenac sodium. International Journal of Pharm Tech Research. 2009 Oct;1(4):1507-11.
51. Yairi MB, inventor; Los Gatos Research Inc, assignee. Transdermal patch system. United States patent application US 12/100, 250. 2009 Oct 15.
52. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nature Reviews Drug Discovery. 2004 Feb;3(2):115.
53. Prausnitz MR. Microneedles for transdermal drug delivery. Advanced Drug Delivery Reviews. 2004 Mar 27;56(5):581-7.
54. Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB, Gong J, Williams KE, Reeves KR. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008 Aug 1;63(8):717-24.
55. Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterials. 2008 May 1;29(13):2113-24.
56. Thomas BJ, Finnin BC. The transdermal revolution. Drug Discovery Today. 2004 Aug 1;9(16):697-703.
57. Cormier M, Johnson B, Ameri M, Nyam K, Libiran L, Zhang DD, Daddona P. Transdermal delivery of desmopressin using a coated microneedle array patch system. Journal of Controlled Release. 2004 Jul 7; 97(3):503-11.
58. Yairi MB, inventor; Los Gatos Research Inc, assignee. Transdermal patch system. United States Patent Application US 12/100,250. 2009 Oct 15.
59. Kusum Devi V, Saisivam S, Maria GR, Deepti PU. Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. Drug Development and Industrial Pharmacy. 2003 Jan 1;29(5):495-503.
60. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease––rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry: A Journal of The Psychiatry of Late Life and Allied Sciences. 2007 May;22(5):456-67.
61. George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry. 2000 Nov 1;157(11):1835-42.
62. Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, Creasy GW, ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA. 2001 May 9;285(18):2347-54.
63. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. European Journal of Pharmaceutical Sciences. 2001 Sep 1;14(2):101-14.
64. Wick JJ, Weimann LJ, Pollock WC, inventors; Mylan Technologies Inc, assignee. Transdermal patch incorporating a polymer film incorporated with an active agent. United States Patent US 6,010,715. 2000 Jan 4.
65. Mutalik S, Udupa N. Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations. Journal of Pharmaceutical Sciences. 2004 Jun 1; 93(6):1577-94.
66. Arora P, Mukherjee B. Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. Journal of Pharmaceutical Sciences. 2002 Sep;91(9):2076-89.
67. Lee JW, Choi SO, Felner EI, Prausnitz MR. Dissolving microneedle patch for transdermal delivery of human growth hormone. Small. 2011 Feb 18;7(4):531-9.
68. Tiffany ST, Cox LS, Elash CA. Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. Journal of Consulting and Clinical Psychology. 2000 Apr;68(2):233.
69. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs. 2003 Oct 1;63(19):1999-2010.
70. Eppstein J, McRae S, Smith A, inventors; Altea Therapeutics Corp, assignee. Transdermal drug delivery patch system, method of making same and method of using same. United States Patent US 7,392,080. 2008 Jun 24.